We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2021 to May 2024
By Colin Kellaher
AbbVie Inc. on Tuesday said the European Commission approved the expanded use of its cancer drug Venclyxto in combination with a hypomethylating agent for the treatment of adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The North Chicago, Ill., biopharmaceutical company said the approval is based on a Phase 3 study in which patients who received Venclyxto in combination with the hypomethylating agent azacitidine showed statistically significantly greater median overall survival than patients receiving azacitidine alone.
AbbVie and Roche Holding AG are jointly developing Venclyxto, which is approved for indications in chronic lymphocytic leukemia and acute myeloid leukemia. The drug is jointly marketed by AbbVie and Roche's Genentech in the U.S., and by AbbVie alone outside the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 25, 2021 08:55 ET (12:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
